1152 related articles for article (PubMed ID: 29731394)
1. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Hellmann MD; Callahan MK; Awad MM; Calvo E; Ascierto PA; Atmaca A; Rizvi NA; Hirsch FR; Selvaggi G; Szustakowski JD; Sasson A; Golhar R; Vitazka P; Chang H; Geese WJ; Antonia SJ
Cancer Cell; 2018 May; 33(5):853-861.e4. PubMed ID: 29731394
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Owonikoko TK; Park K; Govindan R; Ready N; Reck M; Peters S; Dakhil SR; Navarro A; Rodríguez-Cid J; Schenker M; Lee JS; Gutierrez V; Percent I; Morgensztern D; Barrios CH; Greillier L; Baka S; Patel M; Lin WH; Selvaggi G; Baudelet C; Baden J; Pandya D; Doshi P; Kim HR
J Clin Oncol; 2021 Apr; 39(12):1349-1359. PubMed ID: 33683919
[TBL] [Abstract][Full Text] [Related]
3. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS
J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ; López-Martin JA; Bendell J; Ott PA; Taylor M; Eder JP; Jäger D; Pietanza MC; Le DT; de Braud F; Morse MA; Ascierto PA; Horn L; Amin A; Pillai RN; Evans J; Chau I; Bono P; Atmaca A; Sharma P; Harbison CT; Lin CS; Christensen O; Calvo E
Lancet Oncol; 2016 Jul; 17(7):883-895. PubMed ID: 27269741
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
Ready NE; Ott PA; Hellmann MD; Zugazagoitia J; Hann CL; de Braud F; Antonia SJ; Ascierto PA; Moreno V; Atmaca A; Salvagni S; Taylor M; Amin A; Camidge DR; Horn L; Calvo E; Li A; Lin WH; Callahan MK; Spigel DR
J Thorac Oncol; 2020 Mar; 15(3):426-435. PubMed ID: 31629915
[TBL] [Abstract][Full Text] [Related]
7. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
Reck M; Schenker M; Lee KH; Provencio M; Nishio M; Lesniewski-Kmak K; Sangha R; Ahmed S; Raimbourg J; Feeney K; Corre R; Franke FA; Richardet E; Penrod JR; Yuan Y; Nathan FE; Bhagavatheeswaran P; DeRosa M; Taylor F; Lawrance R; Brahmer J
Eur J Cancer; 2019 Jul; 116():137-147. PubMed ID: 31195357
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
12. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Sharma P; Pachynski RK; Narayan V; Fléchon A; Gravis G; Galsky MD; Mahammedi H; Patnaik A; Subudhi SK; Ciprotti M; Simsek B; Saci A; Hu Y; Han GC; Fizazi K
Cancer Cell; 2020 Oct; 38(4):489-499.e3. PubMed ID: 32916128
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T; William WN; Weissferdt A; Leung CH; Lin HY; Pataer A; Godoy MCB; Carter BW; Federico L; Reuben A; Khan MAW; Dejima H; Francisco-Cruz A; Parra ER; Solis LM; Fujimoto J; Tran HT; Kalhor N; Fossella FV; Mott FE; Tsao AS; Blumenschein G; Le X; Zhang J; Skoulidis F; Kurie JM; Altan M; Lu C; Glisson BS; Byers LA; Elamin YY; Mehran RJ; Rice DC; Walsh GL; Hofstetter WL; Roth JA; Antonoff MB; Kadara H; Haymaker C; Bernatchez C; Ajami NJ; Jenq RR; Sharma P; Allison JP; Futreal A; Wargo JA; Wistuba II; Swisher SG; Lee JJ; Gibbons DL; Vaporciyan AA; Heymach JV; Sepesi B
Nat Med; 2021 Mar; 27(3):504-514. PubMed ID: 33603241
[TBL] [Abstract][Full Text] [Related]
17. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
Klein O; Kee D; Gao B; Markman B; da Gama Duarte J; Quigley L; Jackett L; Linklater R; Strickland A; Scott C; Mileshkin L; Palmer J; Carlino M; Behren A; Cebon J
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782426
[TBL] [Abstract][Full Text] [Related]
19. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
O'Byrne KJ; Lee KH; Kim SW; Park K; Nishio M; Sakai H; Ohe Y; Fukuhara T; Kang JH; Daga H; Yu CJ; Hotta K; Tanaka H; Takeda M; Yokoyama T; Nathan FE; Lee JS
ESMO Open; 2022 Feb; 7(1):100394. PubMed ID: 35158207
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
